Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052739 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
A Phase 1 study of Super-refractory Status Epilepticus, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 17
- Study locations
NCT02052739 is a Phase 1 study of Super-refractory Status Epilepticus that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 25 participants. The trial reports 17 study locations across 12 states.
The verdict
NCT02052739, a Phase 1 study of Super-refractory Status Epilepticus, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
Conditions Studied
Interventions
- DRUG SAGE-547
Study Locations (17)
Massachusetts
- Sage Investigational Site - Boston
- Sage Investigational Site - Boston
Michigan
- Sage Investigational Site - Ann Arbor
- Sage Investigational Site - Detroit
New York
- Sage Investigational Site - New York
- Sage Investigational Site - Rochester
North Carolina
- Sage Investigational Site - Durham
- Sage Investigational Site - Winston-Salem
Texas
- Sage Investigational Site - Dallas
- Sage Investigational Site - Temple
Alabama
- Sage Investigational Site - Birmingham
Florida
- Sage Investigational Site - Sarasota
Illinois
- Sage Investigational Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-03-21 |
| Est. Completion | 2015-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052739
The ClinicalTrials.gov registry entry for NCT02052739 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Super-refractory Status Epilepticus appearing as the primary indexed condition, and to 1 intervention - of which SAGE-547 is the first listed.
NCT02052739 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT02052739 about?
NCT02052739 is a clinical study titled "Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus". The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
What is the current status of trial NCT02052739?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-03-21. Estimated completion is 2015-05-03.
What conditions does trial NCT02052739 study?
This clinical trial studies the following conditions: Super-refractory Status Epilepticus.
What interventions are being tested in trial NCT02052739?
The interventions under investigation include: SAGE-547 (DRUG).
Who is sponsoring clinical trial NCT02052739?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02052739 being conducted?
This trial has 17 study locations across Alabama, Florida, Illinois, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.